Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

Oculis announced that its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops failed to meet the primary endpoint of improved best corrected visual acuity (BCVA) in diabetic macular edema patients at week 52, despite showing substantial retinal thickness reduction. The company will not pursue FDA filing for OCS-01 in DME and will redirect resources to its Privosegtor and Licaminlimab programs. Oculis maintains a strong financial position with $278 million in cash runway into 2H 2029.